Objective The authors assessed whether brain changes detected by diffusion tensor (DT) MRI can improve the understanding of structural damage in Alzheimer's disease (AD) and are associated with different risks of conversion to AD in amnestic mild cognitive impairment (aMCI). Methods Twenty-one aMCI patients, 21 AD patients and 20 healthy subjects underwent conventional and DT MRI at baseline. All subjects were clinically followed up over 2 years; at the end of follow-up, aMCI were grouped into converters to AD (aMCI-C) and nonconverters (aMCI-NC). The mean diffusivity (MD) and fractional anisotropy (FA) were obtained from total grey matter (GM) and white matter (WM), and from several GM and WM regions of interest (ROIs). On T1-weighted images, normalised volumes of the whole brain (NBV), GM (NGMV) and WM were measured. Results A significant 'trend' of worsening with a trajectory 'normal/aMCI/AD' was found for NBV and NGMV, total GM and WM MD, total WM FA, as well as for diffusivity abnormalities in several GM and WM ROIs, mainly located in posterior brain regions. aMCI-C had GM and WM changes similar to those seen in AD, whereas aMCI-NC showed a DT MRI pattern similar to that of healthy subjects. DT MRI metrics that better distinguished aMCI-C from aMCI-NC were MD of total GM and WM, hippocampi, anterior insulae, frontal and parietal WM, occipital GM and WM, and FA of temporal WM. Volumetric variables were not able to distinguish the two aMCI subgroups (aMCI-C and aMCI-NC). Conclusions Subtle brain diffusivity changes occur from the prodromal stages of AD, mainly in posterior brain regions, and spread over the course of the disease to involve the frontal lobe. In aMCI, the severity of microstructural damage within and beyond the medial temporal lobe is associated with an increased short-term risk to develop AD.
INTRODUCTION
Mild cognitive impairment (MCI) is considered to be a transitional stage between normal ageing and dementia. Amnestic MCI (aMCI) subjects convert to Alzheimer's disease (AD) at a rate three-to sixfold higher than the normal elderly population. However, not all patients with aMCI go on to develop AD. In some patients, the cognitive deficits may stabilise; in others, they may improve or progress to other phenotypes of dementia. 1 Compared with non-converters, aMCI who evolve to AD typically show a more severe atrophy of the medial temporal lobe (MTL), the inferior and middle temporal gyrus, the posterior cingulate and the precuneus. 2 Diffusion tensor (DT) MRI has made it possible to detect microstructural brain changes in patients with AD, which go undetected when using conventional MRI. 3e5 Increased diffusivity has been demonstrated in the grey matter (GM) of patients with AD compared with healthy elderly subjects mainly in the hippocampi and in the temporal and parietal cortices. 4 5 Most likely, increased GM diffusivity reflects loss of neurons and dendrites, which causes an enlargement of the extracellular spaces and, hence, reduces the 'barriers' limiting water molecular motion. 5 DT MRI studies also showed AD-related subtle changes in the white matter (WM) of the temporal, parietal and frontal lobes, the corpus callosum and the cingulum.
3 5e7 These findings agree with neuropathological data indicating a loss of myelin sheaths, axons and oligodendrocytes in AD brains. 8 DT MRI studies have also attempted to elucidate the earliest point at which such changes can be detected by focusing on patients with aMCI. 5 9 10 aMCI patients were found to harbour diffusivity alterations in brain regions that are typically involved in early AD, especially in the hippocampi. 5 Previous DT MRI studies, which assessed the predictive value of structural brain changes for conversion to AD, limited their analysis to the MTL. Hippocampal diffusivity measurements have been found to be more sensitive than hippocampal atrophy in predicting conversion to AD in these patients. 11 12 To date, no prospective studies have considered the prognostic value of brain DT MRI measures beyond the MTL.
The aim of this longitudinal study was to assess whether GM and WM microstructural changes detected by DT MRI can improve the understanding of structural damage in clinically probable AD and have the ability to predict the conversion to AD in aMCI patients. Patients with aMCI were scanned at baseline, then entered a longitudinal clinical followup of 2-year duration, which allowed them to be classified as aMCI converters (aMCI-C) and nonconverters (aMCI-NC). First, we tested whether DT MRI variables from total GM and WM as well as from several specific regions-of-interest (ROIs) in both GM and WM were characterised by a significant worsening over the trajectory 'normal/aMCI/AD.' Then, we evaluated the ability of DT MRI metrics, volumetric MRI and neuropsychological tests at baseline in distinguishing aMCI-C from aMCI-NC.
MATERIALS AND METHODS Patients
Patients were enrolled consecutively from the population attending the Outpatient Dementia Clinic of our Institution. Clinical diagnosis was based on a multidisciplinary evaluation including neurological examination and a neuropsychological test battery. Inclusion criteria for all patients were: (a) no evidence of depression or disthymia; (b) normal laboratory tests, including vitamin B 12 , folate and thyroid hormone levels; (c) no metabolic diseases or substance abuse that could interfere with cognitive functioning; and (d) no other major systemic, psychiatric or neurological illnesses. The history of type 2 diabetes, hypertension and heart disease was explored. Heart disease included a history of atrial fibrillation, other arrhythmias, congestive heart failure, myocardial infarction and angina pectoris. In addition, as suggested in the past 3 and in order to minimise the inclusion of subjects with significant cerebrovascular disorder, individuals with evidence of concomitant cerebral vascular disease on conventional MRI scans (ie, one hyperintense area with a diameter equal or greater than 5 mm, or more than four hyperintensities smaller than 5 mm in diameter on T2 weighted scans) were excluded.
Twenty-one patients with aMCI, 21 patients with clinically probable AD and 20 healthy subjects were recruited (table 1) . Patients with aMCI reported a subjective memory complaint, showed abnormal memory performance for their age and did not display functional impairment in activities of daily living according to care giver report. 1 Patients with probable AD met the criteria established by the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRA) and were in the mild range of the disease based on Clinical Dementia Rating (CDR) scale scores, 13 which ranged from 1 to 2 (ie, with mild or moderate cognitive deficits). Healthy controls had no memory complaints and no evidence of cognitive deficits on formal neuropsychological testing, no history of systemic, neurological and psychiatric disorders, and an MRI which was normal or where evidence of cerebrovascular disease met the exclusion criteria described above. Two subjects (one aMCI and one AD) had a history of type 2 diabetes, 17 subjects (four controls, seven aMCI and six AD) suffered from hypertension, and three aMCI patients had a history of atrial fibrillation.
At baseline, within 48 h from acquisition of the MR images, an extensive neuropsychological battery was administered by a trained neuropsychologist. General intellectual functioning was assessed using the Mini Mental State Examination (MMSE), 14 and the total functional assessment was measured using the CDR. 13 Memory assessment included an episodic longterm (Delayed Recall Test) 15 scales were also administered. All neuropsychological testing scores were corrected for age and level of education. aMCI patients were re-evaluated every 6 months, and the assessment of whether subjects had progressed to clinically probable AD was made though a consensus committee meeting, as previously described. 23 The diagnosis of probable AD was made according to the NINCDS-ADRDA criteria. 24 The study was approved by the Local Ethics Committee. All subjects provided written informed consent before entering the study.
MRI data acquisition
Brain MR scanning was performed on a magnet operating at 1.5 T (Vision, Siemens, Erlangen, Germany). On a single occasion, the following pulse sequences were obtained from all subjects without moving them from the scanner: (1) 25 The duration and maximum amplitude of the diffusion gradients were respectively 25 ms and 21 mT m À1 , giving a maximum b factor in each direction of 1044 s mm À2 . Fat saturation was performed using a four-radio-frequency binomial pulse train to avoid chemical shift artefacts. For the DE and T1-weighted images, the slices were positioned to run parallel to a line that joins the most inferoanterior and inferoposterior parts of the corpus callosum. The PGSE images were acquired with the same orientation as the DE scans, and with the second-last caudal slice positioned to match exactly the central slices of the DE set.
MRI analysis and postprocessing
MR images were transferred to a workstation (Sun Sparcstation; Sun Microsystem, Mountain View, California) for analysis, which was performed by consensus by two experienced observers unaware of subjects' identities. An experienced radiologist reviewed the severity of WM hyperintensities according to the Wahlund rating scale. 26 On T1-weighted images, NA, not applicable.
normalised volumes of the whole brain (NBV), GM (NGMV) and WM (NWMV) were measured using the cross-sectional version of the Structural Image Evaluation of Normalised Atrophy (SIENAx) software. 27 The computation of the DT was performed using an in-house developed software. First, the distortion in the diffusionweighted (DW) images caused by eddy currents was corrected. 28 Then, the DT was estimated by linear regression, 29 and MD and FA maps calculated. 30 The b¼0 images of the PGSE scans (T2, but non-DW-weighted) were then coregistered with the corresponding T2-weighted images, 28 and the same transformation parameters applied to the MD and FA maps. GM and WM were segmented as previously described. 31 This generated mutually exclusive masks for each tissue, which were superimposed onto the MD and FA maps. MD histograms of the total GM and WM, and FA histograms of the WM were produced. 32 FA histograms were derived only for the WM, since no preferential water molecular motion is expected to occur in the GM.
DT MRI metrics were also derived from regions of interest (ROIs) within GM and WM. First, rectangular ROIs of variable size (range¼8.6e15.3 mm 2 ), depending on the anatomical region studied, were carefully placed on the T2-weighted images to avoid partial volume averaging from the cerebrospinal fluid (CSF). ROIs were drawn bilaterally in the following regions: amygdala, hippocampus, head of the caudate nucleus, thalamus, posterior limb of the internal capsule, genu and splenium of the corpus callosum, anterior and posterior cingulate gyri, and anterior insular cortex (figure 1). ROIs were also placed in the GM and WM of the four cerebral lobes (figure 1). Amygdala and hyppocampus ROIs were positioned on the slice including the mesencephalus where these two structures are easily identifiable. Thalamus was sampled in its medial portion, where fibres associated with temporal lobes are preferentially located. Anterior and posterior cingulate ROIs were positioned on the slice showing the genu and the splenium of the corpus callosum, anteriorly and posteriorly to these structures, respectively. Anterior insular cortex ROIs were placed on the slice including the trigone of the lateral ventricle, the basal ganglia and the Sylvian fissure. In the frontal lobe, GM ROIs were drawn on the cortex of the middle frontal gyrus, while the frontal WM ROIs were placed on the boundary between the superior and the middle frontal gyri. Parietal GM and WM ROIs were positioned, respectively, on the postcentral gyrus, and posterior to the central sulcus in the centrum semiovale above the ventricles. Temporal GM ROIs were placed on the middle temporal gyrus, while WM ROIs were positioned anterior-laterally to the temporal horn of the lateral ventricle. Finally, occipital GM ROIs were placed on the calcarine cortex medially to the occipital horn of the lateral ventricle, and occipital WM ROIs laterally to the optic radiations. The ROIs were then superimposed onto the corresponding coregistered MD (figure 1) and FA maps of each subject. Average MD was calculated for GM and WM ROIs; for the reason given above, the average FA was measured for WM ROIs, only.
Statistical analysis
To assess the intrarater reproducibility of the ROI analysis, DT MRI measurements were obtained twice in a blinded fashion in nine randomly selected subjects (three from each of the three groups). For each pair of measurements (separated by a period of 1 week), the intraclass correlation coefficients were calculated. Lefteright differences of DT-MRI values derived from ROI analysis were assessed using a t test for paired data; since no lefteright difference was found (data not shown), the mean of the values obtained from the two hemispheres entered the statistical analysis. An analysis of variance (ANOVA) model with each of the neuropsychological, volumetric and DT MRI metrics as the dependent variable and a three-level variable ('trend-variable'; ie, healthy controls, aMCI patients and AD patients) as the independent covariate ('test for trend') was used Figure 1 Anatomical locations of the regions of interest (ROIs) on T2-weighted images (top row) and coregistered mean diffusivity maps (bottom row) from a healthy control: (A) ROI 1¼temporal grey matter (GM), ROI 2¼temporal white matter (WM); (B) ROI 3¼amygdala, ROI 4¼hippocampus; (C) ROI 5¼occipital WM, ROI 6¼occipital GM, ROI 7¼head of the caudate nucleus, ROI 8¼posterior limb of the internal capsule, ROI 9¼anterior insula, ROI 10¼frontal GM, ROI 11¼frontal WM; (D) ROI 12¼thalamus, ROI 13¼genu of the corpus callosum, ROI 14¼splenium of the corpus callosum, ROI 15¼anterior cingulate gyrus, ROI 16¼posterior cingulate gyrus; (E) ROI 17¼parietal GM, ROI 18¼parietal WM.
to investigate the trajectory 'normal/aMCI/AD.' Those variables showing a trend to worsen along such a trajectory were then tested at a second-level analysis. For each neuropsychological and MRI metric selected in the first step, a multivariate model with a stepwise selection procedure was performed including two different variables: (1) the three-level variable used for the trend analysis ('trend-variable') and (2) a two-level stratification, where aMCI-NC were grouped with healthy controls and aMCI-C with AD patients ('split-group variable'). The stepwise selection procedure investigated whether aMCI could be considered, on the basis of the neuropsychological and MRI variables, as an intermediate condition between normality and AD (including in the final model the 'trend-variable,' only), or as consisting of two different subgroups, being one similar to controls and the other to AD patients (including in the final model the 'split-group variable,' only). Statistical analyses were repeated by entering the subject's age, and brain volumes in case of DT MRI measures, as covariates.
RESULTS

Clinical and neuropsychological data
No healthy control converted to aMCI or AD during the followup period. Two aMCI patients refused to return for the followup visits and were excluded from further analyses. Of the remaining 19 aMCI patients, 11 (58%) progressed to AD over 2 years (aMCI-C; six women and five men, mean age 71 years (range¼57e79 years), mean disease duration 20 months (range¼6e36)), while eight patients did not (aMCI-NC; two women and six men, mean age 69 (range¼52e79), mean disease duration 26 months (range¼12e56)). No differences in demographic and clinical findings were found between aMCI-NC and aMCI-C patients. In 
Neuroimaging results
The Wahlund rating scale score was 0 in all subjects. Table 3 shows the volumetric measurements of total brain, GM and WM and DT MRI-derived metrics of total GM and WM from the subject groups.
The mean intraclass correlation coefficient for DT MRI-based ROI analysis was 0.87 (SD¼0.04). Table 4 shows the DT MRIderived metrics of selected ROIs from the subject groups.
A significant 'trend' over the trajectory 'normal/aMCI/AD' was found for NBV and NGMV, as well as for total GM and WM MD (figure 2), and total WM FA (table 3) . Moreover, a significant 'trend' was shown for MD and FA values of several ROIs. In particular, a significant 'trend' towards increased MD values was found in the hippocampus, thalamus, posterior cingulate gyrus, anterior insula, genu of the corpus callosum, frontal WM, and parietal and occipital GM and WM (table 4) . A 'trend' towards decreased FA values was found in the frontal, temporal and occipital WM (table 4). After adjustment for subject's age and brain volumes, a significant 'trend' was found for total WM MD, MD of the parietal GM, MD of the frontal and occipital WM, and FA values of the temporal WM. Within the aMCI group, values from patients who progressed to AD during follow-up (aMCI converters (aMCI-C)) and those who did not (aMCI non-converters (aMCI-NC)) are also shown.
Results are means, with SD in parentheses.
*p Values refer to 'trend analysis' (see text for further details).
yVariables that better distinguish between the two aMCI subgroups (aMCI-C and aMCI-NC)dmultivariate model with a stepwise selection procedure (see text for further details).
The multivariate model with a stepwise selection procedure showed that volumetric variables were not able to distinguish between the two aMCI subgroups (aMCI-C and aMCI-NC). On the contrary, DT MRI variables that better distinguish between the two aMCI subgroups included MD of total GM and WM, hippocampus, anterior insula, frontal and parietal WM, and occipital GM and WM, and FA values of temporal WM (tables 3, 4, figure 2 ).
DISCUSSION
The main aims of this 2-year prospective study were to improve the understanding of structural damage in clinically probable AD, and to investigate whether brain microstructural changes detected by DT MRI could offer an insight into the development of AD in patients with aMCI. First, we found a trend towards increased MD and decreased FA values along the trajectory 'normal/aMCI/AD.' Second, in aMCI patients, the severity of brain diffusivity and anisotropy changes within and beyond the MTL were associated with an increased short-term risk of conversion to AD. Conversely, volumetric measurements were not able to distinguish between aMCI-C and aMCI-NC patients. This suggests that DT MRI has the potential to provide useful markers to predict subsequent progression to AD in patients with aMCI.
The pattern of GM damage along the trajectory 'normal/ aMCI/AD' is typical of that observed in previous pathological and neuroimaging studies. 2 5 33 As expected, 2e5 33 a significant 'trend' of worsening was found not only for total GM atrophy but also for global GM DT MRI metrics. Regional DT MRI analysis also showed that, when subjects have a clinical diagnosis of AD, the pattern of GM damage is diffuse, since it involves not only the MTL but also the parieto-occipital association cortices, as well as the frontal lobes. Increased GM MD in aMCI and AD patients may result from loss of neuron cell bodies, synapses and dendrites, which in turn may cause an increase in extracellular spaces, 5 and hence abnormal diffusivity values. The MTL is known to be one of the first structures to be involved in AD pathology. 34 Post-mortem studies showed that most patients with MCI already have the pathological hallmarks of ADdneocortical senile plaques, neurofibrillar tangles, atrophy and neuronal lossdin the hippocampus 35 and entorhinal cortex. 36 Our finding of an increased GM damage beyond the MTL also agrees with the previous pathological and imaging literature. 5 37 38 Indeed, this fits well with the Braak and Braak neurofibrillar pathological staging scheme in AD, which indicates that the disease starts mainly in the hippocampus and entorhinal cortex, and subsequently spreads throughout temporal, posterior cingulate and frontal cortices. 34 Another intriguing finding of our study is that WM changes, which occur before the onset of clinically overt dementia, also progress along the trajectory 'normal/aMCI/AD,' and that they may play a role in the cognitive decline leading to AD. There are several possible explanations for changes of WM integrity in aMCI and AD. First, the early deposition of amyloid around neuronal cell bodies and accumulation of s in neuronal cells in GM may lead to anterograde Wallerian degeneration, especially in regions close to cortical areas with the greatest pathological burden. Second, the occurrence of vascular disease with AD, due to amyloid angiopathy and/or arteriosclerosis, can cause axonal damage and gliosis. Third, as has recently been suggested, 39 myelin breakdown is likely to be an important component of the disease process in AD, which may also constitute a critical initiating step. Our finding of a posterior WM involvement agrees with many previous DT MRI studies in AD patients. 9 10 Regions located in the posterior WM, such as the parietal and temporal lobes, have being consistently found to be affected also in patients with MCI. 7 In agreement with the notion that the disease progresses to a multidomain clinical and cognitive syndrome from aMCI to AD, we found that WM damage increased also in the anterior brain regions, such as the genu of the corpus callosum and the frontal lobe. More controversial is the observation of diffusivity abnormalities in the occipital lobe. Previous DT MRI studies in AD and MCI patients have resulted in mixed observations. 3 9 40e42 However, recent post-mortem studies demonstrated occipital pathological changes early in the course of the disease, 43 and PET studies of AD patients showed amyloid deposition and reduced cerebral glucose metabolism in posterior associative regions, including the occipital cortex. 37 The discrepancy of findings across different DT MRI studies may be due to methodological and subject selection differences.
The major result of this study was that DT MRI findings are useful in predicting short-term conversion to AD in patients with aMCI, while volumetric measurements did not. More than half (58%) of our aMCI patients deteriorated during the follow-up and fulfilled the criteria for diagnosing clinically probable AD. This is in agreement with previous studies on the conversion rate of aMCI. 1 When compared with aMCI-NC, aMCI-C showed greater structural abnormalities in both GM and WM. Moreover, the stepwise selection procedure showed that aMCI-C had a pattern of DT MRI abnormalities similar to that seen in patients with AD, whereas aMCI-NC showed DT MRI values similar to those of healthy subjects. Our finding of increased diffusivity changes in aMCI patients who progressed to AD strengthen and expand the results from previous neuroimaging studies. 12 44 Indeed, most of the previous MRI studies limited their analysis to the assessment of pathology within the MTL, whereas our study showed that the presence and severity of tissue damage beyond the MTL are also associated with a short-term risk of developing clinically probable AD in aMCI patients.
Several studies demonstrated that measures of hippocampal volume are associated with time to progression from MCI to AD (see Chong and Sahadevan 45 for a review). In a recent MRI study of 190 aMCI subjects, the rate of progression of MTL atrophy was associated with a significantly increased risk of developing dementia within 3 years. 46 In addition, previous DT MRI studies showed that aMCI patients have increased MD values in brain regions that are typically involved in early AD, especially in the hippocampi, 5 and two other studies found that increased hippocampal diffusivity predicts progression to AD in aMCI as well as, if not better, than hippocampal atrophy, 11 12 thus indicating that DT MRI is sensitive to hippocampal microscopic alterations, which may be apparent earlier than the atrophy changes measured with volumetric approaches.
In the present study, we showed, using regional betweengroup analyses, that MD values are diffusely altered, while the anatomical pattern of WM anisotropy changes is greater in the posterior than in the anterior regions of the brain. More interestingly, a more severe damage in the insular and occipital cortices and the lobar WM was found in aMCI-C when compared with aMCI-NC. As a consequence, one may speculate that a higher risk for conversion to AD in aMCI patients is associated with both greater damage in disease-specific regions and an early involvement of regions usually damaged later in the course of AD.
This study is not without its limitations. The main limitation is the relatively small sample size, which was nevertheless comparable with those of previous reports. 5 9 11 12 Due to the exploratory nature of our study, we did not correct for multiple comparisons, and so some of the significances might have been overestimated. However, our findings offer a priori hypotheses to be tested in future, larger studies. The presence of brain atrophy is likely to have increased the impact of the partial volume effect from the CSF on DT MRI findings, especially because of the use of 6 mm thick slices. This choice was dictated by an attempt to reduce the length of the acquisition timed which was deemed necessary in not-fully compliant patients, such as those with moderate ADdwhile still achieving a good signal-to-noise ratio and covering the entire brain. However, in our analysis, particular attention was paid to minimise this issue. ROIs were carefully placed on the T2-weighted images to keep away from the CSF and then moved to the coregistered DT MRI maps. The good quality of ROI placement and registration can be appreciated in figure 1 . When we ran the analysis of DT MRI changes with correction for GM and WM volumes, the data demonstrated that GM and WM atrophy did account for differences in some areas. However, significant MD increase and FA decrease remain across several regions including the parietal cortex and temporal lobe, which are known to be among the structures mostly involved in AD pathology. Since we did not acquire high-resolution T1-weighted images, and, as a consequence, we did not investigate the topographical distribution of GM and WM tissue loss, we cannot completely rule out that the possibility that a systematic increase in MD and a systematic decrease in FA might have occurred in small structures. Future studies using high-resolution DT MRI and T1-weighted MRI to measure volumes of specific brain structures in larger patient sample are necessary to validate our findings. Figure 2 Plots describing mean diffusivity (MD) of total grey matter and white matter of Alzheimer's disease (AD) patients, amnestic mild cognitive impairment (aMCI) patients who progressed to AD (aMCIconverters¼aMCI-C), aMCI patients who did not progress (aMCI non-converters¼aMCI-NC) and healthy controls. MD is expressed in units of mm 2 3s À1 310 3 . Each box represents the IQR, which contains 50% of individual subjects' values. The whiskers are lines that extend from the box to the highest and lowest values, excluding outliers. A line across the box indicates the median value.
